Predictive factors for tumor response to chemotherapy in patients with pancreatic cancer

Hepato-Gastroenterology

Volumn 47, Issue 36, 2000, Pages 1744-1746

  Fujishiro, M ^a   Okada, S ^a   Ueno, H ^a   Okusaka, T ^a   Ikeda, M ^a   Watanabe, H ^a   Tanaka, N ^a  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

Author keywords

Pancreatic cancer; Predictive factors; Systemic chemotherapy; Tumor response

Indexed keywords

ALBUMIN; ANTINEOPLASTIC AGENT; BILIRUBIN; CARCINOEMBRYONIC ANTIGEN; CISPLATIN; DOCETAXEL; EPIRUBICIN; FLUOROURACIL; GEMCITABINE; IRINOTECAN; METHOTREXATE; TEGAFUR;

ADULT; AGED; ALBUMIN BLOOD LEVEL; ARTICLE; CANCER CHEMOTHERAPY; DISEASE ASSOCIATION; FEMALE; HUMAN; HYPOALBUMINEMIA; JAUNDICE; MAJOR CLINICAL STUDY; MALE; PANCREAS ADENOCARCINOMA; PANCREAS RESECTION; PERITONEUM METASTASIS; PREDICTION; PRIORITY JOURNAL;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS; BIOLOGICAL MARKERS; FEMALE; HUMANS; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; PROGNOSIS; RETROSPECTIVE STUDIES;

EID: 0033637821     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Phase II studies of drug combinations in advanced pancreatic carcinoma: Fluorouracil plus doxorubicin plus mitomycin C and two regimens of streptozotocin plus mitomycin C plus fluorouracil
2. Continuous 5-fluorouracil (5-FU) infusion in carcinoma of the pancreas: A phase II study
3. Lack of efficacy of high-dose leucovorin and fluorouracil in patients with advanced pancreatic adenocarcinoma
4. Fluorouracil and high-dose leucovorin in previously untreated patients with advanced adenocarcinoma of the pancreas: Results of a phase II trial
5. A phase III comparison trial of streptozotocin, mitomycin, and 5-fluorouracil with cisplatin, cytosine arabinoside, and caffeine in patients with advanced pancreatic carcinoma
6. Phase R evaluation of fluorouracil and recombinant alpha-2a-interferon in previously untreated patients with pancreatic adenocarcinoma
7. Phase II study of cisplatin and 120-hour continuous infusion of 5-fluorouracil in patients with advanced pancreatic adenocarcinoma
8. A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer
9. Phase II study of gemcitabine in patients with advanced pancreatic cancer
10. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial
11. Toxicity and response criteria of the Eastern Cooperative Ontology Group
12. Prognostic factors in patients with advanced pancreatic cancer treated with systemic chemotherapy
13. Phase I and pharmacokinetic trial of paclitaxel in patients with hepatic dysfunction: Cancer and Leukemia Group B 9264